Relay Stock Soars on Upbeat Data From Breast Cancer Study

Shares of Relay Therapeutics (RLAY) soared 52.4% on Sept. 9 after the company announced positive interim data from the early-stage study of its lead investigational candidate, RLY-2608, to treat heavily pretreated breast cancer patients. The enrolled population included PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer (MBC) patients who received the combo regimen of twice-daily, 600 mg dose of RLY-2608 and AstraZeneca's (AZN) Faslodex (fulvestrant). Interim data from the study showed t ...